Clinical Trials Archive - Page 14 of 16

recruiting PHASE1 Respiratory / COPD / Asthma NCT06637371

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants…

Sponsor: Amgen

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 Cardiology / Cardiovascular NCT05668741

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic…

Sponsor: Vertex Pharmaceuticals Incorporated

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06890598

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with…

Sponsor: Eli Lilly and Company

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Sponsor: Sumitomo Pharma America, Inc.

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 Cardiology / Cardiovascular NCT05734196

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.

Sponsor: Inozyme Pharma

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Cardiology / Cardiovascular NCT04774159

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients…

Sponsor: Population Health Research Institute

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Mental Health / Psychiatry NCT06466135

Study of WAL0921 in Patients With Glomerular Kidney Diseases

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic…

Sponsor: Walden Biosciences

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Respiratory / COPD / Asthma NCT07088068

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency…

Sponsor: Sanofi

View Trial ClinicalTrials.gov ↗

recruiting NA Oncology NCT06803771

Surveillance of Pancreatic Health After Diabetes Diagnosis

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within…

Sponsor: University Hospital Southampton NHS Foundation Trust

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Cardiology / Cardiovascular NCT07157774

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of…

Sponsor: Eli Lilly and Company

View Trial ClinicalTrials.gov ↗

Clinical Trials

Join 10,000+ UK Clinicians